Event Date/Time: Nov 03, 2003
End Date/Time: Nov 04, 2003
With the development of RNAi: Breaking Through the Target Validation and In Vivo Therapeutic Bottlenecks, IBC continues to be the leading information provider in therapeutic applications of this unique gene-silencing tool. Join us at IBC’s 2nd International Conference on RNAi for two days of focused sessions from leading companies and research organizations. Hear Dr. Hans Winkler discuss how Johnson & Johnson is using siRNA in target validation and listen to a presentation by Dr. Xiaomin Schebye on how the DNAX Research Institute of Schering Plough is furthering in vitro validation of targets specific to cancer therapeutics. On the delivery front, Dr. Cy Stein of the Albert Einstein College of Medicine will discuss successes and failures of applying antisense delivery to RNAi as Dr. David Lewis of Mirus Corporation discusses challenges in delivery to mammalian cells. Other leading companies sharing valuable insight include Cold Spring Harbor Laboratories, Beckman Research Institute, Alnylam Pharmaceuticals, Harvard Medical School, Stanford University, and Santaris A/S to name a few.